Lantern Pharma (Nasdaq: LTRN) launched withZeta.ai today with a private investor briefing at Nasdaq MarketSite in New York City, bringing 25 biotech investors and analysts together to see the platform’s live multi-agent research workflows in action. The platform is now commercially available with subscriptions open across introductory, academic, and commercial tiers, according to PharmiWeb.
The company describes withZeta.ai as “the world’s first and most comprehensive multi-agentic AI co-scientist for rare cancer drug discovery, development, biomedical research, molecular design and clinical trial development.” That claim has not been independently verified by tier-1 editorial outlets, but the platform itself is real and accepting subscribers.
What It Does
withZeta.ai is the commercial evolution of Lantern Pharma’s RADR platform, an oncology-focused experimental biology and molecular analysis system the company originally built for its own cancer programs. The multi-agent architecture handles real-time querying across multiple databases, molecule development for rare cancer indications, and clinical trial planning, according to Morningstar.
The “co-scientist” framing positions the platform as a research partner for human oncologists and drug developers rather than a replacement. Multiple specialized AI agents work in parallel across different tasks: querying clinical trial databases, analyzing genomic data, evaluating molecule interactions, and synthesizing findings into drug development guidance.
Two Launch Events
Today’s Nasdaq MarketSite demonstration (12:00 PM to 2:00 PM Eastern) was an invitation-only event targeting the institutional investment community. The broader scientific debut starts tomorrow at the American Association for Cancer Research (AACR) Annual Meeting 2026 in San Diego (Booth 5054, April 17 through 22), per the PharmiWeb report. AACR is the premier academic conference for cancer research, drawing over 20,000 attendees annually, and is where the scientific community will evaluate the platform’s capabilities.
Revenue and Business Model
For Lantern Pharma shareholders, withZeta.ai represents a new non-dilutive revenue stream. The subscription model (introductory, academic, and commercial tiers) means recurring revenue from researchers and institutions using the platform, separate from Lantern’s clinical-stage oncology pipeline. The company is positioning the commercial deployment directly to institutional analysts and investors through the Nasdaq MarketSite event, according to StockTitan.
Life Sciences Joins the Agent Deployment Wave
withZeta.ai is notable for where it sits in the market. Life sciences drug discovery is among the highest-stakes, most data-intensive domains where multi-agent coordination could deliver meaningful acceleration. Rare cancers specifically suffer from small patient populations and limited trial data, making AI-assisted pattern recognition across fragmented databases potentially valuable. The platform’s launch adds life sciences to the list of distinct industry verticals that shipped dedicated AI agent capabilities this week, alongside manufacturing, creative tools, financial services, and mobile development.